drug development
Mining Spider Toxins for Analgesic Clues
Mining Spider Toxins for Analgesic Clues
Catherine Offord | Jan 1, 2018
Arachnids harbor a plentiful array of molecules that target mammalian pain receptors.
Researchers Mine Centipede Toxins for Analgesics
Researchers Mine Centipede Toxins for Analgesics
Catherine Offord | Jan 1, 2018
Venomous centipedes may harbor a clue to the creation of a successful pain-killing compound for humans.
Novel Analgesics at a Snail’s Pace
Novel Analgesics at a Snail’s Pace
Bob Grant | Jan 1, 2018
Studying cone snail venom has yielded novel pain pathways, but the peptides that function as toxins are difficult to translate into drugs.
Animal Analgesics
Animal Analgesics
The Scientist Staff | Jan 1, 2018
A cornucopia of toxins in the animal kingdom could provide inspiration for novel painkillers, but so far, effective drugs have proven elusive.
 
Snake Venoms Cause and Block Pain
Snake Venoms Cause and Block Pain
Kerry Grens | Jan 1, 2018
Painful snake bites may hold clues to developing analgesic drugs.
Infographic: A Painful Pathway
Infographic: A Painful Pathway
Catherine Offord | Dec 31, 2017
Since the mid-2000s, the voltage-gated sodium channel NaV1.7 has emerged as a promising target for a new class of analgesics.
Painful Realities
Painful Realities
The Scientist Staff | Dec 31, 2017
Dave Thomas, a researcher at the National Institute on Drug Abuse, talks about the harsh truths and frustrating complexity of pain and analgesia.
Hormonal Male Contraceptive to Enter Clinical Trial
Hormonal Male Contraceptive to Enter Clinical Trial
Jef Akst | Dec 21, 2017
The gel, which men rub on their upper bodies daily, delivers synthetic progestin to block the testes from producing normal levels of sperm.
New CAR T-Cell Therapy Shows Promise in Trial for Leukemia
New CAR T-Cell Therapy Shows Promise in Trial for Leukemia
Katarina Zimmer | Nov 21, 2017
The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful. 
RNA Interference Drug Excels in Clinical Trials to Treat Rare Disorder
RNA Interference Drug Excels in Clinical Trials to Treat Rare Disorder
Katarina Zimmer | Nov 3, 2017
If approved, patisiran will be the first RNAi therapeutic on the market.